Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages.
Clinical practice guideline
Diagnosis
Fertility preservation
Germ cell tumour of the testis
Prognosis
Staging
Journal
Urologia internationalis
ISSN: 1423-0399
Titre abrégé: Urol Int
Pays: Switzerland
ID NLM: 0417373
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
06
2020
accepted:
23
06
2020
pubmed:
8
1
2021
medline:
23
7
2021
entrez:
7
1
2021
Statut:
ppublish
Résumé
This is the first German evidence- and consensus-based clinical guideline on diagnosis, treatment, and follow-up on germ cell tumours (GCTs) of the testis in adult patients. We present the guideline content in two publications. Part I covers the topic's background, methods, epidemiology, classification systems, diagnostics, prognosis, and treatment recommendations for the localized stages. An interdisciplinary panel of 42 experts including 1 patient representative developed the guideline content. Clinical recommendations and statements were based on scientific evidence and expert consensus. For this purpose, evidence tables for several review questions, which were based on systematic literature searches (last search was in March 2018) were provided. Thirty-one experts entitled to vote, rated the final clinical recommendations and statements. We provide 161 clinical recommendations and statements. We present information on the quality of cancer care and epidemiology and give recommendations for staging and classification as well as for diagnostic procedures. The diagnostic recommendations encompass measures for assessing the primary tumour as well as procedures for the detection of metastases. One chapter addresses prognostic factors. In part I, we separately present the treatment recommendations for germ cell neoplasia in situ, and the organ-confined stages (clinical stage I) of both seminoma and nonseminoma. Although GCT is a rare tumour entity with excellent survival rates for the localized stages, its management requires an interdisciplinary approach, including several clinical experts. Quality of care is highly related to institutional expertise and can be reassured by established online-based second-opinion boards. There are very few studies on diagnostics with good level of evidence. Treatment of metastatic GCTs must be tailored to the risk according to the International Germ Cell Cancer Collaboration Group classification after careful diagnostic evaluation. An interdisciplinary approach as well as the referral of selected patients to centres with proven experience can help achieve favourable clinical outcomes.
Identifiants
pubmed: 33412555
pii: 000510407
doi: 10.1159/000510407
pmc: PMC8006579
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
169-180Informations de copyright
© 2021 The Author(s). Published by S. Karger AG, Basel.
Références
J Clin Oncol. 2008 Jun 20;26(18):2966-72
pubmed: 18458040
Urol Oncol. 2014 Jan;32(1):33.e1-6
pubmed: 23395239
J Urol. 1996 Apr;155(4):1296-8
pubmed: 8632558
Ann Oncol. 2018 Feb 1;29(2):341-346
pubmed: 29140422
Acta Oncol. 2015 Apr;54(4):493-9
pubmed: 25192551
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
CMAJ. 2010 Dec 14;182(18):E839-42
pubmed: 20603348
Eur Urol. 2011 Apr;59(4):556-62
pubmed: 21190791
Eur Urol. 2004 Aug;46(2):209-14; discussion 214-5
pubmed: 15245815
J Clin Oncol. 2015 Jan 1;33(1):51-7
pubmed: 25135991
Eur Urol. 1993;23(4):444-9
pubmed: 7687549
Aktuelle Urol. 2014 Nov;45(6):454-6
pubmed: 25514778
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Ann Intern Med. 2013 Feb 19;158(4):280-6
pubmed: 23420236
Ann Oncol. 2010 Sep;21(9):1858-1863
pubmed: 20142410
J Clin Oncol. 1997 Feb;15(2):594-603
pubmed: 9053482
Urology. 2004 Mar;63(3):556-61
pubmed: 15028457
Klin Onkol. 2015;28(2):112-5
pubmed: 25882021
Eur Urol. 2008 Mar;53(3):497-513
pubmed: 18191015
J Clin Oncol. 2014 Dec 1;32(34):3817-23
pubmed: 25267754
J Clin Oncol. 1996 Feb;14(2):441-8
pubmed: 8636755
Asian Pac J Cancer Prev. 2015;16(8):3267-72
pubmed: 25921130
Ann Oncol. 2005 Dec;16(12):1915-20
pubmed: 16126737
J Natl Cancer Inst. 1999 May 19;91(10):839-46
pubmed: 10340903
Eur Urol. 2008 Mar;53(3):478-96
pubmed: 18191324
BMC Med Res Methodol. 2007 Feb 15;7:10
pubmed: 17302989
J Urol. 1999 Apr;161(4):1148-52
pubmed: 10081858
Urol Oncol. 2011 Mar-Apr;29(2):189-93
pubmed: 19362863